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rishnaswamy Chandrasekaran, MD, FACC,* Michael D. McGoon, MD, FACC*
ochester, Minnesota
OBJECTIVES We sought to determine the predictors of short-term morbidity and mortality (30 days)
after noncardiac surgery in patients with pulmonary hypertension (PH).
BACKGROUND Pulmonary hypertension is considered to be a significant preoperative risk factor.
METHODS The PH and surgical data bases were matched from 1991 to 2003. Patients were excluded if
PH was secondary to left heart disease, not present before surgery, or the procedure involved
cardiopulmonary bypass. Univariate and multivariate logistic regression analyses were used to
identify variables associated with short-term morbidity and mortality.
RESULTS Of 1,276 patients in the PH database, 145 patients (73% female) met all study criteria. The
mean age (SD) was 60.1  16.0 years. Right ventricular systolic pressure (RVSP) (mean 
SD) on the two-dimensional echocardiogram was 68  21 mm Hg. There were 60 patients
(42%) who experienced one or more short-term morbid event(s) (1.8 events/patient
experiencing any event). A history of pulmonary embolism (p  0.01), New York Heart
Association functional class II (p  0.02), intermediate- to high-risk surgery (p  0.04),
and duration of anesthesia 3 h (p  0.04) were independent predictors of short-term
morbidity. There were 10 early deaths (7%). A history of pulmonary embolism (p  0.04),
right-axis deviation (p  0.02), right ventricular (RV) hypertrophy (p  0.04), RV index of
myocardial performance 0.75 (p  0.03), RVSP/systolic blood pressure 0.66 (p  0.01),
intraoperative use of vasopressors (p 0.01), and anesthesia when nitrous oxide was not used
(p  0.01) were each associated with postoperative mortality.
CONCLUSIONS In patients with PH undergoing noncardiac surgery with general anesthesia, specific clinical,
diagnostic, and intraoperative factors may predict worse outcomes. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.0552005;45:1691–9) © 2005 by the American College of Cardiology Foundation
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rurgery poses a significant risk for patients with pulmonary
ypertension (PH) (1,2). Right ventricular (RV) failure,
ersistent postoperative hypoxia, and coronary ischemia are
mong the potential perioperative complications (1,3). Pre-
perative mean pulmonary artery pressure (MPAP) 30
m Hg has been shown to be a significant independent
redictor of postoperative mortality in over 2,000 patients
ndergoing cardiopulmonary bypass (2). Increased periop-
rative morbidity and mortality of adult patients with PH
ave been described previously in case reports, small series,
nd retrospective analyses of surgical data bases (1–10).
owever, most of these reports have focused on cardiopul-
onary surgeries, often with cardiopulmonary bypass. Such
perations, independent of the presence of PH, carry an
levated risk of morbidity and mortality compared with
any noncardiac operations (11–13).
The primary aim of this study was to evaluate the
ncidence of perioperative (30 days) morbidity and mor-
ality in adult patients with PH undergoing noncardiac
From the *Division of Cardiovascular Diseases, Department of Internal Medicine,
nd †Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester,
innesota.M
Manuscript received November 17, 2004; revised manuscript received February 2,
005, accepted February 8, 2005.urgery with general anesthesia at a large tertiary care
edical center. We investigated multiple baseline demo-
raphic characteristics, clinical parameters, and intraopera-
ive interventions to determine the specific variables that
ay be associated with the occurrence of short-term post-
perative complications. Secondary analyses focused on
dentification of parameters that were associated with an
ncreased length of hospital stay (LOS) after surgery.
ETHODS
tudy population. The study protocol was approved by the
ayo Foundation Institutional Review Board. The PH
lectronic data base was cross-referenced with the data base
f all patients who had undergone monitored anesthesia
are, deep sedation/analgesia, or general anesthesia from
uly 1991 to December 2003 at our medical center. All
atients with resting two-dimensional Doppler echocardio-
raphic (2D echo) right ventricular systolic pressure (RVSP)
35 mm Hg were included in the study. Patients were
xcluded if age at the time of surgery was 18 years,
tiology for PH was considered left heart disease, consent to
esearch authorization was not given (as mandated ininnesota Statute 144.335), PH was not clinically diag-
n
o
s
b
A
(
a
(
w
s
d
p
i
d
H
l
s
c
h
a
h
a
d
o
(
n
f
d
a
h
p
c
p
t
v
k
d
t
c
h
s
a
s
I
r
c
a
c
a
o
f
(
a
a
p
w
I
r
a
u
b
e
r
c
i
o
p
O
c
p
s
a
“
f
t
i
D
i
h
d
o
t
o
(
o
m
w
e
f
r
i
n
d
a
p
c
1692 Ramakrishna et al. JACC Vol. 45, No. 10, 2005
Pulmonary Hypertension and Postoperative Outcomes May 17, 2005:1691–9osed before surgery, or the procedure involved neuraxial or
ther regional anesthesia, monitored anesthesia care, cardiac
urgery, or any other surgery requiring cardiopulmonary
ypass.
nalysis of preoperative factors. One of the authors
G.R.) reviewed the medical records of all eligible patients
nd extracted demographic, clinical, and diagnostic data
Table 1). Right heart catheterization and 2D echo data
ere included if performed within three years of the index
urgical date. The 2D echo performed closest to the surgical
ate was used if there were multiple 2D echo scans
erformed. The standard 6-min walk test (6MWT) was
ncluded if performed within two years of the index surgical
ate. Major comorbid conditions were defined according to
osking et al. (14) and have been referenced in epidemio-
ogic studies from our institution’s Department of Anesthe-
iology. The major comorbidities identified were cardiovas-
ular disease (pharmacologically treated systemic
ypertension, coronary artery disease, history of or current
trial fibrillation, history of deep venous thrombosis, or
istory of cerebrovascular disease [stroke, transient ischemic
ttack, or previous carotid endarterectomy]), pulmonary
isease (chronic thromboembolic pulmonary disease or
bstructive or restrictive pulmonary disease), hepatic disease
hepatitis, cirrhosis, hepatopulmonary syndrome, hepatore-
al syndrome, portal hypertension, or aspartate aminotrans-
erase45 U/l), renal disease (creatinine2 mg/dl or use of
ialysis), connective tissue disease (systemic lupus erythem-
tosus, scleroderma, or mixed connective tissue disease),
ematologic malignancy (leukemia, lymphoma, myelodys-
lastic syndrome, or hyperviscosity syndrome), and pharma-
ologically treated diabetes mellitus.
As part of the standard 2D echo examination, the
resence of RV hypertrophy was determined by assessing
he RV wall thickness from multiple views. The right
entricular index of myocardial performance (RVIMP), also
nown as the RV Doppler Tei index, was calculated by
ividing the sum of RV isovolumic relaxation and contrac-
ion times by the ejection time interval (15–18) and was
ategorized as abnormal if 0.75. Hemodynamic studies
ave used the ratio of pulmonary vascular resistance to
Abbreviations and Acronyms
2D echo  two-dimensional Doppler echocardiogram
IQR  interquartile range
LOS  length of hospital stay
MPAP  mean pulmonary artery pressure
6MWT  six-minute walk test
NYHA  New York Heart Association
PH  pulmonary hypertension
RV  right ventricular
RVIMP  right ventricular index of myocardial
performance
RVSP  right ventricular systolic pressure
SBP  systolic blood pressureystemic vascular resistance (0.50 to 0.74 [moderate PH] cnd 0.75 [severe PH]) to account for the influence of
ystemic hypertension on pulmonary artery pressure (19,20).
n our study, PH was considered at least moderate if the
atio of right ventricular systolic pressure (RVSP) to con-
urrent systemic systolic blood pressure (SBP) was 0.66
nd severe if 0.66. The left atrial volume index was
alculated as the product of left atrial areas obtained in the
pical two-chamber and four-chamber views times the lesser
f the length obtained in the apical two-chamber and
our-chamber views 0.85 divided by the body surface area
21). Pulmonary function tests were classified as normal or
bnormal (obstructive, restrictive, or mixed pattern). In
ccordance with standard protocol (22), the 6MWT was
erformed in a level corridor, and patients were instructed to
alk at their own pace.
ntraoperative factors. Data extracted from the operative
ecord included duration of anesthesia (referenced to start
nd end time of general anesthetic), inhalation anesthetic
sed, and intraoperative administration of beta-adrenergic
lockers and major vasopressor agents (i.e., dopamine,
pinephrine). The type of surgery was categorized as low
isk (breast, dermatologic, ear, nose, and throat/oral, gyne-
ologic, neurologic, plastic/reconstructive, and urologic) or
ntermediate to high risk (gastrointestinal/major abdominal,
rthopedic, thoracic, vascular, and transplant [liver, kidney,
ancreas]).
utcome measures. The occurrence of perioperative out-
ome events was determined from the review of hospital
rogress notes, postanesthesia care unit records, discharge
ummary note, and follow-up outpatient notes. For this
nalysis, we considered morbid events and fatal events as
early” if they occurred intraoperatively or were 30 days
rom the date of surgery. The LOS was determined from
he date of noncardiac surgery to dismissal date (or date of
n-hospital death) of the patient.
efinition of morbidity. We specifically defined morbid-
ty as the occurrence of any of the following: 1) congestive
eart failure: new pulmonary edema, elevated jugular venous
istension 10 mm Hg, or lower extremity edema and use
f diuretic or afterload- and/or preload-reducing medica-
ions, or physician documentation that the patient devel-
ped congestive heart failure; 2) cardiac ischemic events
electrocardiographic ST-segment elevation or depression
f 1 mm or elevated or inverted T waves) with or without
yocardial infarction (appearance of new Q waves 0.04 s
ide and 1 mV in depth accompanied by troponin T
levation 0.03 ng/ml or elevation in creatine kinase-MB
raction [100 IU/l and MB band 5%]; 3) stroke; 4)
espiratory failure: prolonged intubation 24 h or re-
ntubation, tracheostomy placement, or pneumonia/hypoxia
ecessitating postoperative oxygen therapy in patients who
id not require it preoperatively; 5) hepatic dysfunction:
spartate aminotransferase45 U/l in a patient with normal
reoperative aspartate aminotransferase or 50% elevation
ompared with baseline; 6) renal insufficiency: increase in
reatinine to 2 mg/dl in a patient with normal preopera-
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nd/or initiation of hemodialysis; 7) sepsis or hemodynamic
nstability necessitating inotropic/vasopressor support; and
) cardiac dysrhythmia: new-onset atrial fibrillation, su-
raventricular tachycardia, bradycardia with conduction
lock, or ventricular tachycardia/fibrillation.
efining the cause of mortality. Major causes of death
ere derived from autopsy and/or clinician reports; patients
ould have one or more cause(s) of death. Congestive heart
ailure, myocardial infarction, respiratory failure, liver/renal
ysfunction, stroke, and sepsis/hemodynamic instability
ere coded as previously defined.
tatistical analyses. Data are summarized with count and
ercentage data for nominal or dichotomous variables and
ean  SD or median and interquartile range (IQR) (25th
o 75th percentile) for continuous variables. Clinical vari-
bles potentially predictive of short-term morbidity and
ortality were first identified by logistic regression analysis,
hich assessed the association of each characteristic with
he respective outcome. Multivariate logistic regression
nalysis was modeled using a stepwise variable selection
rocedure to identify variables with the strongest indepen-
ent association with morbidity. Variables deemed clinically
elevant and all variables with p  0.20 in the univariate
odel were considered for inclusion in the multivariate
ogistic regression model.
For each characteristic, the median LOS and IQR
ere reported. The LOS displayed a markedly right-
kewed, nonparametric distribution, and thus log LOS
as used as the dependent variable. Univariate linear
egression analysis was used to assess the association of
ach characteristic with log LOS. Multivariate linear
egression analysis was performed with respect to log
OS using the stepwise variable selection procedure, as
erformed for the morbidity model.
We used JMP 5.1 statistical software (2003 SAS Insti-
ute, Inc., Cary, North Carolina) for all analyses. For both
nivariate and multivariate analyses, p  0.05 was necessary
able 1 Continued
Characteristic n (%)
iagnostic and hemodynamic data n† Mean  SD
6-min walk distance (m) 55 319  111
2D echo RVSP (mm Hg) 145 68  21
Catheterization-derived RVSP (mm Hg) 68 68  22
Catheterization-derived MPAP (mm Hg) 66 44  15
Catheterization-derived wedge
pressure (mm Hg)
65 15  8
Classification modified from Venice 2003 Revised Clinical Classification of PH (23).
atients were categorized as “nonspecific” if multiple co-exisiting factors contributed
o PH or if PH was present in the setting of comorbidities that did not permit a
onfident diagnosis of idiopathic pulmonary arterial hypertension. †Values may be
145, because data variables were not available for all patients.
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor
locker; CABG coronary artery bypass graft surgery; COPD chronic obstructive
ulmonary disease; MPAP  mean pulmonary artery pressure; PCI  percutaneous
oronary intervention; PH  pulmonary hypertension; RVSP  right ventricular
ystolic pressure.able 1. Baseline Characteristics of Patients With Pulmonary
ypertension Undergoing Noncardiac Surgery (n  145)
Characteristic n (%)
emale 106 (73)
ulmonary hypertension*
Pulmonary arterial hypertension
Idiopathic 29 (20)
Associated with
Collagen vascular 18 (12)
Portal hypertension 14 (10)
Congenital systemic to pulmonary
shunts
10 (7)
Other 8 (6)
PH associated with lung diseases and/or
hypoxemia
Lung disease: COPD, interstitial,
restrictive
20 (14)
Obstructive sleep apnea 7 (5)
PH due to chronic thrombotic and/or
embolic disease
12 (8)
Nonspecific 27 (19)
ew York Heart Association functional class
I 39 (27)
II 67 (46)
III/IV 39 (27)
moking status
Never smoker 80 (55)
Ex-smoker (quit 6 months) 55 (38)
Current smoker 10 (7)
reoperative comorbidity
Pulmonary
COPD 38 (26)
Obstructive sleep apnea 23 (16)
Restrictive lung disease 16 (11)
History of pulmonary thromboembolism 12 (8)
Cardiovascular
Systemic hypertension 72 (50)
Coronary artery disease 25 (17)
Previous CABG 14 (10)
Previous PCI 10 (7)
History of or current atrial fibrillation 25 (17)
History of deep venous thrombosis 15 (10)
History of cerebrovascular disease 12 (8)
Other
Liver disease 25 (17)
Renal disease 25 (17)
Connective tissue disease 23 (16)
Diabetes mellitus 18 (12)
Hematologic malignancy 12 (8)
utpatient medication use
Diuretic 79 (54)
Beta-adrenergic blockers 43 (30)
ACE-I/ARB 40 (28)
Calcium channel blocker 40 (28)
Warfarin sodium 41 (28)
Digoxin 25 (17)
Steroid 21 (14)
Epoprostenol 15 (10)
Bosentan 6 (4)
Continuedor retention of variables in the given model.
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reoperative characteristics. Of 1,276 patients in the PH
atabase, 21 denied research authorization (1.6%) and were
xcluded. Of the remaining 1,255 patients, 349 (28%) had
ndergone anesthetic procedures. Patients who had under-
one cardiovascular or pulmonary surgery requiring cardio-
ulmonary bypass as their only recorded surgery (n  65),
atients who had no clinical diagnosis of PH at the time of
urgery (n  69), patients with PH secondary to left heart
isease (n  19), and patients who underwent neuraxial/
ther regional anesthesia or monitored anesthesia care (n 
1) were excluded.
The final study population comprised 145 adult patients
ith PH who had noncardiac surgery with general anesthe-
ia from July 1991 to December 2003. Baseline clinical
haracteristics (including PH classification according to the
enice 2003 guidelines) (23), preoperative outpatient med-
cation use, and baseline hemodynamic data of the study
opulation are provided in Table 1. The mean (SD) age
as 60.1  16.0 years. The RVSP (mean  SD) on 2D
cho was 68  21 mm Hg. The MPAP in the 66 patients
ho underwent right heart catheterization was 44  15
m Hg.
hort-term morbidity. Of 144 patients who survived sur-
ery, 60 (42%) had one or more short-term morbid event(s)
1.8 events/patient experiencing any event). The most
requent postoperative morbid events noted were respiratory
ailure (28%), cardiac dysrhythmia (12%), and congestive
eart failure (11%) (Table 2).
nivariate predictors of short-term morbidity. Patient
reoperative clinical characteristics that were associated with
ncreased short-term morbidity were New York Heart
ssociation (NYHA) functional class II, history of pul-
onary embolism, and presence of obstructive sleep apnea
Table 3). Patients who underwent intermediate- to high-
isk surgery were 2.5 times more likely to experience a
orbid event as compared with patients who had low-risk
urgery (Table 4). Similarly, patients who underwent 3 h
f anesthesia or received intraoperative vasopressor support
ith dopamine or epinephrine were also significantly more
able 2. Incidence and Type of Early (30 Days) Morbidity in
atients With Pulmonary Hypertension (n  145) After
oncardiac Surgery
Morbidity Patients* (n) Frequency (%)
espiratory failure 41 28
ardiac dysrhythmia 17 12
ongestive heart failure 16 11
enal insufficiency 10 7
epsis/hemodynamic instability 10 7
epatic dysfunction 6 4
schemia/myocardial infarction 5 4
troke 1 1
Patients may have had one or more morbid event(s).ikely to suffer short-term morbidity. None of the selected earameters derived from the 6MWT, electrocardiogram, or
D echo were predictive of morbidity (Table 5).
ultivariate predictors of short-term morbidity. A his-
ory of pulmonary embolism, NYHA functional class II,
ntermediate- to high-risk surgery, and duration of anesthe-
ia 3 h were independent predictors of postoperative
hort-term morbidity in the multivariate model (Table 6).
nivariate predictors of early (<30 days) postoperative
ortality. Of 145 surgical procedures, there were 10 early
eaths (7%), one of which occurred during the operation as
complication of RV failure. Respiratory failure (60%) and
V failure (50%) were the most frequent contributing
auses of death (patients could have one or more cause[s] of
eath). The limited number of early deaths precluded robust
ultivariate analysis to identify independent predictors of
arly mortality, and thus, only the univariate analyses are
resented.
Right-axis deviation on the electrocardiogram (p 0.02),
V hypertrophy (p 0.04), RVIMP0.75 (p 0.03), and
VSP/SBP 0.66 (p  0.01) by 2D echo were all signif-
cantly associated with early mortality. A history of pulmo-
ary embolism (p  0.04), anesthesia when nitrous oxide
as not used (p 0.01), and intraoperative use of dopamine
p  0.01) and epinephrine (p  0.01) were also associated
ith early mortality on univariate analysis.
ength of hospital stay. The median (25th, 75th percen-
ile) LOS for all patients was 5 (2, 7) days. NYHA
unctional class II, history of systemic hypertension,
ntermediate- to high-risk surgery, duration of anesthesia
3 h, and intraoperative vasopressor use were each signif-
cantly associated with an increased LOS (Tables 3 to 5).
here was a trend toward increased LOS in patients who
eceived intraoperative acute beta-adrenergic blockade (p 
.09). Patients who were administered anesthesia without
itrous oxide and those who performed 330 m on the
MWT were significantly more likely to have an increased
OS. Patients with any morbidity also had a significantly
reater median LOS (7 days, IQR 4, 15), as compared with
atients without morbidity (3 days, IQR 1, 5.5) (p  0.01).
In the multivariate linear regression analysis, systemic
ypertension, duration of anesthesia 3 h, intraoperative
opamine use, and intermediate- to high-risk surgery were
ach independent predictors of increased LOS (Table 7).
ISCUSSION
his study has demonstrated that several preoperative patient
haracteristics and results from diagnostic tests, as well as
ntraoperative factors, are independent predictors of short-term
erioperative (30 days) morbidity and mortality in adult
atients with PH undergoing noncardiac surgery under general
nesthesia. Information on the perioperative morbidity and
ortality of patients with PH who undergo noncardiac surgery
s scarce. In our study, almost half of the 145 patients studied
n  60 [42%]) experienced at least one short-term morbid
vent and 10 patients had early death (7%).
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tudy demonstrated a 7% perioperative mortality rate, indi-
ating the serious impact of PH. There are no published
ata to provide a direct comparison with our study, as the
ajority of reports have focused on patients with PH who
ave undergone cardiopulmonary bypass (1,5,7,24–29). In
atients with PH undergoing pulmonary thromboendarter-
ctomy, mortality rates have ranged from 4.4% to as high as
4% (28–31). In a retrospective study of 2,066 patients who
nderwent cardiopulmonary bypass, PH was the only base-
ine factor independently predictive of perioperative mortal-
ty (odds ratio 2.1) (2). Others reported a 30-day periop-
rative mortality rate of 5.0% in 59 patients with severe PH
ho underwent mitral valve surgery (32). This is compara-
le to the 7% perioperative mortality rate found in the
resent study.
A few studies have examined the outcomes of patients
able 3. Univariate Association of Patient Demographics and Co
tay* (Days) After Noncardiac Surgery
Characteristic
Patients
n (%)†
ge (yrs)
50 35 (24)
50 110 (76)
ender
Male 39 (27)
Female 106 (73)
ype of pulmonary hypertension
PAH 79 (55)
Other PH 66 (45)
ew York Heart Association functional class
I 39 (27)
II/III/IV 106 (73)
oronary artery disease
No 120 (83)
Yes 25 (17)
iabetes mellitus
No 127 (88)
Yes 18 (12)
ystemic hypertension
No 73 (50)
Yes 72 (50)
ulmonary function
Normal 22 (20)
Abnormal 88 (80)
istory of pulmonary embolism
No 133 (92)
Yes 12 (8)
istory of deep venous thrombosis
No 130 (90)
Yes 15 (10)
bstructive sleep apnea
No 122 (84)
Yes 23 (16)
reatinine (mg/dl)
2.0 129 (89)
2.0 16 (11)
From surgery to hospital discharge. †Values may be 145, because data variables we
ariable. §p  0.02 by the chi-square test for trends with incremental New York H
IQR  interquartile range (25th to 75th percentile); LOS  length of hospital sta
s noted in Table 1; PH  pulmonary hypertension.ith PH undergoing noncardiac surgery (33,34). However,hese series have described PH patients who have an
dditional high-risk clinical condition, and this makes a
irect comparison to our study population problematic.
regnant patients with PH and Eisenmenger’s syndrome
ndergoing caesarean section have a maternal mortality up
o 70% (33). Krowka et al. (34) reported a 35% mortality
ate in patients with PH who underwent orthotopic liver
ransplantation; 93% of the deaths were secondary to
ardiopulmonary compromise and 10 of the 14 deaths
ccurred during the course of hospitalization. In our study,
he type of surgery was significantly associated with in-
reased morbidity, as opposed to mortality. More than half
61.5%) of the patients who underwent thoracic and 48% of
atients undergoing orthopedic surgery experienced mor-
idity, as opposed to 16.7% of patients who underwent
ither gynecologic/urologic or plastic/dermatologic/breast
urgery.
idities With Perioperative Morbidity and Length of Hospital
rbidity
(%) p Value
LOS (Days)
Median (IQR) p Value‡
0.84 0.11
(43) 2 (2–7)
(41) 5 (2–7)
0.14 0.25
(51) 5 (3–8)
(38) 4.5 (2–7)
0.82 0.49
(41) 4 (2–8)
(42) 5 (2–7)
0.01§ 0.01
(23) 3 (1–5)
(48) 5.5 (2–7.25)
0.29 0.49
(43) 5 (2–7)
(32) 4 (2–6.5)
0.20 0.70
(39) 4 (2–7)
(56) 5 (4–6.25)
0.28 0.01
(37) 3 (2–7)
(46) 6 (3–8.75)
0.92 0.64
(45) 3.5 (1.75–7)
(44) 5 (2–7)
0.01 0.55
(38) 5 (2–7)
(75) 6.5 (2.25–13.5)
0.13 0.25
(39) 5 (2–7)
(60) 6 (3–20)
0.04 0.37
(38) 4.5 (2–7)
(61) 5 (3–7)
0.46 0.68
(40) 5 (2–7)
(50) 5 (2.25–7.75)
available for all patients. ‡p values were calculated using log LOS as the dependent
ssociation functional class.
 pulmonary arterial hypertension, as defined per Venice 2003 guidelines (23) andmorb
Mo
n
15
45
20
40
32
28
9
51
52
8
50
10
27
33
10
39
51
9
51
9
46
14
52
8
re not
eart ABecause there is limited information in the literature
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Pulmonary Hypertension and Postoperative Outcomes May 17, 2005:1691–9Table 4. Univariate Association of Operative Characteristics With Perioperative Morbidity and
Length of Hospital Stay* (Days) After Noncardiac Surgery
Characteristic
Patients
n (%)†
Morbidity
n (%) p Value
LOS Median
(IQR) p Value‡
Type of surgery 0.01 0.01
Low risk 31 (21) 6 (19) 2 (0, 4)
Intermediate/high risk 114 (79) 54 (47) 6 (3, 8)
Duration of anesthesia 0.02§ 0.01
3 h 94 (65) 32 (34) 3 (1, 6)
3 h 50 (34) 27 (54) 7 (4, 15)
Intraoperative nitrous oxide 0.09 0.04
No 66 (46) 32 (49) 6 (2, 8.25)
Yes 78 (54) 27 (35) 4 (2, 6.25)
Intraoperative acute beta-blockade 0.18 0.09
No 126 (88) 49 (39) 4.5 (2, 7)
Yes 18 (13) 10 (56) 7 (3.75, 12)
Intraoperative dopamine 0.01 0.01
No 132 (92) 48 (36) 4 (2, 7)
Yes 12 (8) 11 (92) 12 (7, 21)
Intraoperative epinephrine 0.01 0.03
No 133 (92) 49 (37) 4 (2, 7)
Yes 11 (8) 10 (91) 9 (6, 16)
*From surgery to discharge. †Values may be 145, because data variables were not available for all patients. ‡p values calculated
using log LOS as the dependent variable. §p  0.01, duration of anesthesia analyzed as a continuous variable.
Abbreviations as in Table 3.Table 5. Univariate Association of Hemodynamic and Cardiac Performance Characteristics With
Perioperative Morbidity and Length of Hospital Stay* (Days) After Noncardiac Surgery
Patients
n (%)†
Morbidity
n (%) p Value
LOS (Days)
Median (IQR) p Value‡
Echocardiogram
Ejection fraction 0.08 0.41
0.50 9 (6) 1 (11) 3 (1.5–5.5)
0.50 136 (94) 59 (43) 5 (2–7)
Right ventricular hypertrophy 0.67 0.68
No 61 (42) 24 (39) 5 (2–7)
Yes 84 (58) 36 (43) 4.5 (2–7)
RVIMP 0.36 0.34
0.75 106 (90) 45 (42) 5 (2–7)
0.75 12 (10) 3 (25) 3.5 (1–6.75)
RVSP/SBP ratio 0.22§ 0.85
0.66 110 (76) 42 (38) 5 (2–7)
0.66 34 (24) 17 (50) 3 (2–7.25)
Left atrial volume index (ml/m2) 0.13 0.33
27 33 (26) 17 (52) 3 (1.5–7)
27 96 (74) 35 (36) 5 (2–7)
Electrocardiogram
Right atrial enlargement 0.21 0.37
No 131 (90) 52 (40) 5 (2–7)
Yes 14 (10) 8 (57) 5 (2–9.25)
Right ventricular hypertrophy 0.32 0.41
No 130 (90) 52 (40) 5 (2–7)
Yes 15 (10) 8 (53) 2 (1–8)
Right-axis deviation 0.59 0.77
No 119 (82) 48 (40) 5 (2–7)
Yes 26 (18) 12 (46) 3 (2–7.25)
6-min walk test
Distance (m) 0.47 0.03
330 27 (49) 9 (33) 3 (2–5)
330 28 (51) 12 (43) 5.5 (2.25–7.75)
*From surgery to discharge. †Values may be 145, because data variables were not available for all patients. ‡p values calculated
using log LOS as the dependent variable. §p  0.14, RVSP/SBP analyzed as a continuous variable.RVIMP  right ventricular index of myocardial performance; RVSP/SBP  right ventricular systolic pressure/systolic blood
pressure; other abbreviations as in Table 3.
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atients with PH undergoing noncardiac surgery, it is of
nterest to compare our findings to other “high-risk” patient
opulations undergoing noncardiac surgery. In 367 elderly
atients (age 80 years) undergoing noncardiac surgery,
5% experienced adverse postoperative complications (car-
iac, pulmonary, and neurologic) and 4.6% died during their
ospitalization (35). Similarly, in 177 elderly patients (65
ears old) who underwent noncardiac surgery, 22% experi-
nced cardiac or pulmonary complications and 3.4% died
uring their hospitalization (36). In contrast, our study
opulation had a higher perioperative cardiopulmonary
omplication (38%) and mortality rate (7%), as compared
ith the “high-risk” patient populations as described
35,36).
redictors of perioperative morbidity and mortality.
ight ventricular failure was a contributing cause of death in
0% of patients. In addition to a history of pulmonary
mbolism, perioperative mortality was associated with pre-
perative electrocardiographic findings, abnormal 2D echo
arameters, and intraoperative vasopressor use. In our study,
he preoperative RVSP to SBP ratio was significantly
ssociated with short-term mortality. This is consistent with
rowka’s study, in which all patients with MPAP 50 mm
g died, whereas patients with MPAP 35 mm Hg
urvived (34). Miyamoto et al. (22) demonstrated that the
MWT was predictive of mortality in 43 patients with
rimary PH. In contrast, the 6MWT in our study was not
ssociated with early mortality, and it is possible that the
MWT may be more predictive of long-term outcome. In a
igh-risk nonsurgical population of 81 patients with severe
rimary PH, the right atrial index was a univariate predictor
f mortality (37). Our study patients had varying severity
nd different types of PH; this may explain why right atrial
able 6. Variables Considered Independent Predictors in a
ultivariate Logistic Regression Model of Short-Term
orbidity After Noncardiac Surgery
Characteristic p Value OR (95% CI)
istory of pulmonary embolism 0.01 7.3 (1.9–38.3)
ew York Heart Association functional
class II
0.02 2.9 (1.2–7.7)
ntermediate/high-risk surgery 0.04 3.0 (1.1–9.4)
uration of anesthesia 3 h 0.04 2.9 (1.03–4.6)
I  confidence interval; OR  odds ratio.
able 7. Variables Considered Independent Predictors in a
ultivariate Linear Regression Model of Length of Hospital
tay After Noncardiac Surgery*
Characteristic p Value Estimate† (95% CI)
ystemic hypertension 0.01 1.4 (1.1–1.8)
uration of anesthesia 3 h 0.01 1.5 (1.1–1.9)
ntraoperative dopamine use 0.01 1.9 (1.2–2.9)
ntermediate/high-risk surgery 0.01 2.0 (1.5–2.6)
Log length of hospital stay (LOS, days, from surgery to discharge) used as the
esponse given nonparametric distribution of LOS. †Estimate is the additional LOSa
ncurred in the presence, compared with the absence, of the characteristic.
CI  confidence interval.nlargement on the electrocardiogram trended toward but
id not reach statistical significance with respect to short-
erm mortality (p  0.06). In a study of 53 patients with
rimary PH, the RV Doppler Tei index was independently
redictive of cardiac death and lung transplantation (38).
his is consistent with our findings, as RVIMP 0.75 was
ssociated with perioperative mortality.
Respiratory failure was the most frequent perioperative
orbidity encountered in our study (28% of patients). In a
ase series, among six patients who underwent orthotopic
iver transplantation for severe hepatopulmonary syndrome,
he two patients with preexisting PH were oxygen depen-
ent for a longer period of time (39). Other isolated cases
lso suggest that PH may be a major risk factor for
rolonged ventilatory support after cardiac surgery (25).
Intraoperative dopamine and epinephrine use were asso-
iated with increased short-term morbidity and mortality in
ur study population. Use of these agents likely reflects
ntraoperative complications (i.e., hypotension) and the
eed for hemodynamic stabilization. Thus, vasopressor use
ay be more a sign rather than a predictor of increased
hort-term morbidity. Although theirs was not specifically a
H population, Liu and Leung (35) demonstrated that
ntraoperative use of vasopressor agents was associated with
ncreased in-hospital morbidity and mortality after noncar-
iac surgery in a geriatric population.
ength of stay. Baseline functional status (NYHA func-
ional class and 6MWT), history of systemic hypertension,
umerous intraoperative factors, as well as the occurrence of
ny morbid event, were strongly associated with LOS
Tables 3 to 5). In the general geriatric population (35), any
ntraoperative vasopressor use, as well as any morbid event,
as highly associated with LOS. In our multivariate model,
opamine use persisted as an independent predictor of
OS. Although Liu and Leung (35) did not specify preoper-
tive NYHA functional class, a history of congestive heart
ailure was significantly associated with increased LOS in
hat study. However, parameters associated with baseline
unctional status (NYHA functional class and 6MWT) did
ot retain significance in our multivariate model.
tudy limitations. There are limitations inherent to the
etrospective nature of this study. Both known and un-
nown confounding variables may not have been evenly
istributed among patients and thus not accounted for in
he analyses. Although we have identified several variables
ssociated with morbidity, mortality, and LOS in patients
ith PH, we cannot conclude causality. The identified
ariables may be surrogate markers of other unidentified
linical or diagnostic characteristics. Although hospital and
utpatient records were thoroughly reviewed for outcome
vents, some patients may not have sought medical care for
omplications arising after hospital discharge or may have
ought medical care at a different institution. Thus, the
orbidity, mortality, and LOS analyses for PH patients
ndergoing noncardiac surgery may be underestimates. In
ddition, almost 75% of patients were in NYHA functional
c
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rostanoid or endothelin antagonist. The applicability of the
esults of this study to other populations of patients with
H is thus limited.
We also considered patients eligible for the study based
n 2D echo RVSP 35 mm Hg. This deviates from the
998 World Health Organization criteria for PH, in which
PAP 25 mm Hg at rest or 30 mm Hg with exercise
s considered diagnostic (40,41), but less than half of the
tudy population (46%) had catheterization-derived MPAP.
onetheless, we believe the diagnosis of pulmonary hyper-
ension by 2D echo is a reality in daily practice. Several
ublished articles have demonstrated the usefulness, reli-
bility, and accuracy of noninvasive parameters derived by
D Doppler echo in comparison with those obtained by
ardiac catheterization (42–44).
It is also possible that we did not have enough power to
etect smaller but statistically significant associations or
orrelations between certain characteristics and outcome
easures. The limited sample size is especially pertinent to
he limited number of early deaths (n  10), which
recluded any meaningful multivariate analysis. A larger
tudy of adult patients with PH may therefore be warranted.
onclusions. This study suggests that patients with PH
ndergoing noncardiac surgery with general anesthesia carry
n elevated risk of perioperative morbidity and mortality.
ariables in clinical history and intraoperative factors were
redictive of perioperative morbidity. Perioperative mortal-
ty was also associated with preoperative electrocardio-
raphic findings and abnormal 2D echo parameters. In
ddition, systemic hypertension and operative variables were
redictive of an increased duration of hospitalization after
urgery.
Awareness of the preoperative clinical variables and
iagnostic parameters identified in this study may assist the
linician in providing better risk assessment for patients
ith PH in preparation for noncardiac surgery. In addition,
he various factors identified may also predict the prognosis
nd guide expectations for the patient with PH in terms of
hort-term morbidity, mortality, and LOS. Such insight
ay prompt the clinician to adopt a more aggressive
pproach in the hope of improving postoperative outcomes
n this high-risk population.
eprint requests and correspondence: Dr. Krishnaswamy Chan-
rasekaran, 200 First Street SW, Rochester, Minnesota 55905.
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